Trials / Completed
CompletedNCT06386744
Dusquetide for the Treatment of Behcet's Disease
Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behcet's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Soligenix · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dusquetide | 1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks |
Timeline
- Start date
- 2024-11-18
- Primary completion
- 2025-05-23
- Completion
- 2025-06-17
- First posted
- 2024-04-26
- Last updated
- 2025-08-01
Locations
1 site across 1 country: Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06386744. Inclusion in this directory is not an endorsement.